


CLAIMS

1. A compound of formula(I)



wherein

R represents halogen, C₁₋₄ alkyl, cyano, C₁₋₄ alkoxy, trifluoromethyl or trifluoromethoxy;
 R₁ represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R₁ represents a 4, 5 or 6 membered heterocyclic group, wherein said 5 or 6 membered heteroaryl or the 4, 5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH₂)_pR₆, wherein p is zero or an integer from 1 to 4 and R₆ is selected from:

halogen,

C₁₋₄alkoxy,

C₁₋₄alkyl,

C₃₋₇cycloalkyl,

C₁₋₄ alkyl optionally substituted by halogen, cyano or C₁₋₄ alkoxy,

hydroxy,

cyano,

nitro,

trifluoromethyl,

carboxy,

NH(C₁₋₄ alkyl),

N(C₁₋₄ alkyl)₂

NH(C₃₋₇ cycloalkyl),

N(C₁₋₄ alkyl)(C₃₋₇ cycloalkyl);

NH(C₁₋₄alkyl)OC₁₋₄alkoxy),

OC(O)NR₇R₈ ,

NR₈C(O) R₇ or

C(O)NR₇R₈;

R₂ represents hydrogen, or C₁₋₄ alkyl ;

R₃ and R₄ independently represent hydrogen, C₁₋₄ alkyl or R₃ together with R₄ represents C₃₋₇ cycloalkyl;

R₅ represents trifluoromethyl, S(O)_qC₁₋₄ alkyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy, halogen or cyano;

R₇ and R₈ independently represent hydrogen, C₁₋₄ alkyl or C₃₋₇ cycloalkyl;

L is a single or a double bond;

5 n is an integer from 1 to 3;

m is zero or an integer from 1 to 3;

q is zero or an integer from 1 to 2;

provided that

10 a) when L is a double bond, R₁ is not an optionally substituted 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms;

b) the group R₁ is linked to the carbon atom shown as * via a carbon atom;

and

15 c) when the heteroatom contained in the group R₁ is substituted, p is not zero; and pharmaceutically acceptable salts and solvates thereof.

2. A compound as claimed in claim 1 wherein R is halogen (e.g. fluorine or chlorine) and/or a C₁₋₄ alkyl (e.g. methyl) group and n is an integer from 1 to 2.

20

3. A compound as claimed in claim 1 or claim 2 wherein R₅ is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is an integer from 1 to 2.

4. A compound as claimed in any of claims 1 to 3 wherein R₁ is piperidyl, morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl.

25

5. A compound as claimed in any of claims 1 to 4 wherein R is halogen (e.g. fluorine or chlorine) and/or a C₁₋₄ alkyl (e.g. methyl) group and n is an integer from 1 to 2; R₁ is piperidyl, 2-morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl and wherein R₁ is optionally substituted by one or two groups selected from halogen (e.g. fluorine), C₁₋₄ alkyl (e.g. methyl) or ethylC₁₋₄ alkoxy; R₂ and R₃ are independently hydrogen or methyl; R₄ is hydrogen, methyl or together with R₃ is cyclopropyl and R₅ is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is preferably an integer from 1 to 2.

35

6. A compound selected from:

N-(3,5-Bis-trifluoromethyl-benzyl)-3-(4-fluoro-phenyl)-*N*-methyl-3-piperidin-4-yl-propionamide;

N-(3,5-Dichloro-benzyl)-3-(4-fluoro-phenyl)-*N*-methyl-3-piperidin-4-yl-propionamide;

40 *N*-[1-(3,5-Dichloro-phenyl)-ethyl]-3-(4-fluoro-phenyl)-*N*-methyl-3-piperidin-4-yl-propionamide;

- N*-[1-(3,5-Dichloro-phenyl)-ethyl]-3-(4-fluoro-phenyl)-*N*-methyl-3-[1-(2-methoxyethyl)-piperidin-4-yl]-propionamide;
N-(3,5-Dichloro-benzyl)-3-(4-fluoro-phenyl)-3-(4-fluoro-piperidin-4-yl)-*N*-methyl-propionamide;
- 5 *N*-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-{1-[2-(methoxy)ethyl]-4-piperidinyl}propionamide
N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propanamide;
N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-3-(4-fluorophenyl)-3-(4-piperidinyl)propionamide;
- 10 *N*-{[3-bromo-4-(methoxy)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;
N-[(3,5-dimethylphenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;
N-[(3,4-dibromophenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;
N-[(3-fluoro-2-methylphenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-
- 15 piperidinyl)propionamide;
N-{[2-chloro-3-(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;
N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
- 20 *N*-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(2,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-
- 25 piperidinyl)-*N*-methylpropionamide;
N-[(3,5-dibromophenyl)methyl]-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-[(3,5-dibromophenyl)methyl]-3-(3,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
- 30 *N*-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
3-(4-chlorophenyl)-*N*-[(3,5-dibromophenyl)methyl]-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-
- 35 piperidinylidene)propionamide;
N-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinylidene)propionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluoro-2-methylphenyl)-*N*-methyl-3-(1,2,3,6-
- 40 tetrahydro-4-pyridinyl)propionamide;
N-{[(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluoro-2-methylphenyl)-*N*-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)propionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-pyrrolidinyl)propionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-*N*-methylpropionamide;

N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(2-morpholinyl)propionamide;

5 *N*-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-piperidinyl)propionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-pyridinyl)propionamide;

and enantiomers, diastereoisomers, pharmaceutically acceptable salts(e.g hydrochloride)

10 and solvates thereof.

7. A compound selected from

N-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide(diastereoisomer 1);

15 *N*-{(1*S*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide (diastereoisomer 2);



N-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide (diastereoisomer 1);

20 *N*-{[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide (enantiomer 2);

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-*N*-methylpropionamide (diastereoisomer A);

and pharmaceutically acceptable salts(e.g hydrochloride) and solvates thereof.

25 8. A process for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein R₁ has the meaning previously defined or is a protected group thereof, with amine (III)



30 wherein R₂ is C₁₋₄ alkyl or a nitrogen protecting group, followed where necessary by removal of any protecting group.

9. A compound as claimed in any claims 1 to 7 for use in therapy.

35 10. The use of a compound as claimed in any claims 1 to 7 in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins (including

substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

5 11. The use of a compound as claimed in any claims 1 to 7 in the treatment of conditions mediated by tachykinins (including substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

10 12. A pharmaceutical composition comprising a compound as claimed in any claims 1 to 7 in admixture with one or more pharmaceutically acceptable carriers or excipients.

13. A method for the treatment of a mammal, including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins and/or by selective inhibition of the serotonin reuptake transporter protein comprising administration of an effective amount of a compound of formula (I) as claimed
15 in any claims 1 to 7.